Is the 2025-26 Influenza Vaccine Effective?
Yes, the 2025-26 influenza vaccine is effective and should be administered to all persons aged ≥6 months without contraindications, though effectiveness is lower than recent seasons with moderate protection ranging from 22-57% depending on age group and outcome. 1, 2
Guideline-Based Recommendation
The Advisory Committee on Immunization Practices (ACIP) continues to recommend routine annual influenza vaccination for all persons aged ≥6 months who do not have contraindications for the 2025-26 season 1. This recommendation stands despite the emergence of antigenically distinct H3N2 subclade K viruses that have created a partial vaccine mismatch.
Real-World Effectiveness Data
The most recent and comprehensive U.S. data from September 2025-February 2026 demonstrates the following vaccine effectiveness 2:
Children and Adolescents (<18 years):
- 38-41% against outpatient visits
- 41% against hospitalization
- 35% against H3N2 outpatient visits
- 38% against H3N2 hospitalization
- 45-71% against influenza B
Adults (≥18 years):
- 22-34% against outpatient visits
- 30% against hospitalization
- 63% against influenza B
Older Adults (≥65 years):
The Swedish cohort study provides critical mortality data 3:
- 38% protection against any influenza
- 39% protection against hospitalization
- 56% protection against 30-day all-cause mortality after influenza hospitalization
Clinical Context and Interpretation
While these effectiveness estimates are lower than recent influenza seasons, they still represent meaningful clinical protection, particularly against severe outcomes including hospitalization and death 2, 3. The moderate effectiveness despite antigenic mismatch with H3N2 subclade K is explained by cross-reactive antibodies targeting conserved epitopes on HA antigenic sites A, D, and E 4, 5.
International Corroboration:
- Canada: ~40% effectiveness against H3N2 subclade K 6
- France: 28-57% effectiveness across age groups (highest in children 0-17 years at 57%) 7
- China (Beijing): Suboptimal overall VE but moderate protection (45.4%) in children 5-17 years 8
Key Clinical Considerations
Common Pitfall: Do not withhold vaccination based on reports of "vaccine mismatch" or lower effectiveness. Even moderate protection significantly reduces morbidity, mortality, and healthcare burden, especially in high-risk populations 2, 3.
Age-Specific Guidance:
- Children show consistently better vaccine response (38-57% effectiveness) 2, 7
- Older adults benefit most from mortality reduction (56% against death) 3
- Adults 18-64 years show intermediate protection (22-45%) 2, 7
Formulation Updates for 2025-26:
- Children ≤18 years, pregnant women, and all adults should receive thimerosal-free single-dose formulations 1
- FluMist (LAIV3) now approved for self/caregiver administration 1
- Flublok (RIV3) age indication expanded from ≥18 years to ≥9 years 1
Algorithm for Clinical Decision-Making
- Assess eligibility: All persons ≥6 months without contraindications
- Select appropriate formulation: Thimerosal-free for children, pregnant women, and adults
- Vaccinate without delay: Protection is moderate but clinically meaningful
- Prioritize high-risk groups: Older adults (mortality benefit), children (higher VE), pregnant women, immunocompromised
- Do not defer based on antigenic mismatch concerns: Cross-reactive immunity provides protection 4, 5
The evidence unequivocally supports vaccination despite lower effectiveness this season—the alternative of no vaccination results in preventable hospitalizations and deaths.